Wangsu Science & Technology Co.,Ltd. (300017.SZ) Bundle
Curious whether Wangsu Science & Technology Co., Ltd. (300017.SZ) is a resilient growth story or an overvalued tech play? In Q3 2025 the company reported revenue of 1.14 billion CNY (down 12.85% YoY) while trailing twelve months revenue sits at 4.81 billion CNY (TTM), with 2024 annual revenue of 4.93 billion CNY and a ten‑year average growth of 7%; profitability shows a striking rebound-Q3 net income of 243.62 million CNY (up 84.77% YoY), TTM net profit margin of 17.90% and TTM ROE of 8.24%-but liquidity and valuation raise questions: cash and short‑term investments total 8.07 billion CNY even as Q3 free cash flow plunged 60.34% YoY to 61.61 million CNY, the TTM P/E is 36.00 with a forward P/E of 37.29 and an estimated intrinsic value of 5.88 CNY versus a market price of 10.52 CNY (potentially overvalued by 44.10%), alongside a conservative debt profile (debt/equity 6.44%) and a low beta of 0.17-read on to unpack revenue trends, margins, balance sheet strength, valuation nuances and how strategic moves (cloud, cybersecurity, Tencent Cloud partnership, and Akamai's China exit) may reshape the risk/reward for investors
Wangsu Science & Technology Co.,Ltd. (300017.SZ) - Revenue Analysis
Key revenue figures and context for Wangsu Science & Technology Co.,Ltd. across recent periods, underlying productivity metrics, valuation multiples and historical growth trends.
- Q3 2025 revenue: 1.14 billion CNY (down 12.85% year-over-year).
- Trailing twelve months (TTM) revenue: 4.81 billion CNY (up 0.33% YoY).
- Full-year 2024 revenue: 4.93 billion CNY (up 4.81% vs. prior year).
- Revenue per employee: ~2.99 million CNY (1,608 employees).
- Market capitalization: 24.82 billion CNY; price-to-sales (P/S): 5.06.
- 10-year average revenue growth rate: ~7% (stable upward trend).
| Period | Revenue (CNY) | YoY % | Notes |
|---|---|---|---|
| Q3 2025 | 1.14 billion | -12.85% | Quarterly decline signaling near-term softness |
| TTM (to Q3 2025) | 4.81 billion | +0.33% | Nearly flat year-over-year on a rolling basis |
| Full Year 2024 | 4.93 billion | +4.81% | Annual growth maintained |
| Revenue / Employee | 2.99 million | - | Productivity metric based on 1,608 employees |
| Market Cap | 24.82 billion | - | P/S = 5.06 |
| 10-yr Avg Growth | - | ~7% p.a. | Indicates long-term steady expansion |
- Short-term dynamics: the Q3 2025 drop (-12.85% YoY) contrasts with near-flat TTM performance (+0.33%), suggesting quarter-specific pressures rather than a full-year collapse.
- Valuation lens: a P/S of 5.06 on 4.81 billion TTM revenue implies market cap coverage ~24.36 billion CNY (consistent with reported 24.82 billion), reflecting investor willingness to pay a premium for growth/stability.
- Operational efficiency: revenue per employee (~2.99 million CNY) signals relatively high per-capita revenue, useful when benchmarking peers in CDN/cloud services and tech infrastructure.
- Historical context: a 10-year average growth of ~7% provides a baseline for long-term revenue trajectory versus recent volatility.
- Further detail and corporate background: Wangsu Science & Technology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money
Wangsu Science & Technology Co.,Ltd. (300017.SZ) - Profitability Metrics
Key profitability indicators for Wangsu Science & Technology Co.,Ltd. highlight improving earnings, strong margins and disciplined cost control through 2025.
- Net income (Q3 2025): 243.62 million CNY, up 84.77% year-over-year.
- Net income (H1 2025): 373 million CNY, up 25.33% year-over-year.
- Trailing twelve-month (TTM) net profit margin: 17.90%.
- Earnings per share (EPS, Q3 2025): 0.0994 CNY (vs. 0.054 CNY in Q3 2024).
- Return on equity (TTM ROE): 8.24%.
- Operating margin: 11.56%.
| Metric | Value | Period / Comparison |
|---|---|---|
| Net income | 243.62 million CNY | Q3 2025 (+84.77% YoY) |
| Net income | 373 million CNY | H1 2025 (+25.33% YoY) |
| Net profit margin (TTM) | 17.90% | Trailing 12 months |
| EPS | 0.0994 CNY | Q3 2025 (vs. 0.054 CNY in Q3 2024) |
| Return on equity (ROE) | 8.24% | Trailing 12 months |
| Operating margin | 11.56% | Latest reported |
Contextual notes and investor-relevant takeaways:
- The sharp YoY jump in Q3 2025 net income (84.77%) and rising EPS indicate either revenue acceleration, margin expansion or both; operating margin of 11.56% supports improved operational efficiency.
- A TTM net profit margin of 17.90% signals effective cost management relative to revenue; combined with ROE of 8.24%, the company is delivering moderate shareholder returns on equity.
- Sequential H1 and Q3 results (373M CNY in H1; 243.62M CNY in Q3) show sustained profitability through 2025, strengthening the earnings base for the full year.
For background on corporate strategy, ownership and how the business drives these financial results, see: Wangsu Science & Technology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money
Wangsu Science & Technology Co.,Ltd. (300017.SZ) - Debt vs. Equity Structure
Wangsu Science & Technology Co.,Ltd. displays a conservative capital structure with equity clearly dominating its balance sheet. Total liabilities stand at 1.85 billion CNY against total equity of 10.27 billion CNY, producing a low total debt-to-equity ratio of 6.44%. This signals limited financial leverage and greater balance-sheet resilience in downturns.- Total liabilities: 1.85 billion CNY
- Total equity: 10.27 billion CNY
- Total debt-to-equity ratio: 6.44%
- Enterprise Value / EBITDA: 28.72 (moderate valuation multiple)
- Price-to-Book (P/B): 2.52 (market values assets above book)
- Beta: 0.17 (low volatility vs. market)
- Effective tax rate (Q3 2025): 15.04%
| Metric | Value | Interpretation |
|---|---|---|
| Total liabilities | 1.85 billion CNY | Short + long-term obligations on the balance sheet |
| Total equity | 10.27 billion CNY | Shareholders' capital and retained earnings |
| Total debt-to-equity | 6.44% | Conservative leverage; equity-heavy financing |
| EV / EBITDA | 28.72 | Moderate valuation relative to operating earnings |
| Price-to-Book (P/B) | 2.52 | Market assigns premium over book value |
| Beta | 0.17 | Low historical volatility vs. broader market |
| Effective tax rate (Q3 2025) | 15.04% | In line with standard corporate tax levels |
- Low leverage reduces financial risk but may limit return amplification from debt.
- P/B of 2.52 and EV/EBITDA of 28.72 indicate investors pay a premium for asset quality and earnings stability.
- Beta of 0.17 suggests defensive equity behavior within portfolios.
Wangsu Science & Technology Co.,Ltd. (300017.SZ) - Liquidity and Solvency
Wangsu Science & Technology's balance-sheet strength is driven by a sizeable cash position and moderate asset returns. Key figures point to solid short-term liquidity but weakening operating cash generation in the most recent quarter.- Cash & short-term investments: 8.07 billion CNY (▲ 23.08% YoY)
- Total assets: 12.12 billion CNY
- Return on assets (ROA): 2.66%
- Operating cash flow (Q3 2025): 419.77 million CNY (▼ 17.77% YoY)
- Free cash flow (Q3 2025): 61.61 million CNY (▼ 60.34% YoY)
| Metric | Value (CNY) | YoY Change | Notes |
|---|---|---|---|
| Cash & Short-term Investments | 8,070,000,000 | +23.08% | Primary liquidity cushion |
| Total Assets | 12,120,000,000 | - | Base for solvency ratios |
| Return on Assets (ROA) | 2.66% | - | Modest asset profitability |
| Operating Cash Flow (Q3 2025) | 419,770,000 | -17.77% | Year-over-year decline in OCF |
| Free Cash Flow (Q3 2025) | 61,610,000 | -60.34% | Significant YoY contraction |
- Implication: strong liquid reserves reduce short-term solvency risk, but declining operating and free cash flows warrant attention to earnings quality and working-capital dynamics.
- Investor focus: monitor upcoming cash-flow trends, capex levels, and any changes to debt structure that could affect solvency metrics.
Wangsu Science & Technology Co.,Ltd. (300017.SZ) - Valuation Analysis
Wangsu's current market pricing signals a premium valuation relative to historical earnings and intrinsic estimates. Key market multiples and valuation metrics as of July 1, 2025 show elevated investor expectations and a notable gap between market price and an intrinsic value estimate.| Metric | Value | Interpretation |
|---|---|---|
| TTM Price-to-Earnings (P/E) | 36.00 | Premium vs. many peers; implies significant growth priced in |
| Forward P/E | 37.29 | Market expects continued or accelerating earnings growth |
| Enterprise Value / Revenue (EV/Rev) | 3.71 | Market pays ~3.7x annual revenue for the business |
| Enterprise Value / EBITDA (EV/EBITDA) | 28.72 | High earnings multiple, indicating expensive cash-flow valuation |
| Intrinsic Value (Estimated) | 5.88 CNY | DCF/valuation model-based estimate used here |
| Current Market Price | 10.52 CNY | Observed market trading price |
| Implied Overvaluation | 44.10% | Market price is ~44.10% above estimated intrinsic value |
| Market Capitalization | 25.53 billion CNY | Company size as of July 1, 2025 |
- High TTM P/E (36.00): Suggests investors are pricing robust historical profitability and/or scarce comparable alternatives; increases sensitivity to earnings disappointments.
- Forward P/E > TTM P/E (37.29): Implies expected near-term EPS growth is modest relative to price appreciation, or consensus earnings forecasts are conservative while price momentum persists.
- EV/Revenue of 3.71: For revenue-centric comparisons, this places Wangsu above typical low-margin infrastructure peers-market expects scalable margins or higher recurring revenue quality.
- EV/EBITDA of 28.72: Indicates a stretched valuation on operating cash flows; small changes in EBITDA or discount rates materially affect intrinsic value.
- Intrinsic value 5.88 CNY vs. price 10.52 CNY: Quantifies a 44.10% premium in market pricing-signals potential downside if growth assumptions fail to materialize.
- Earnings growth trajectory vs. consensus - P/E ratios demand sustained earnings expansion.
- Margin improvement and EBITDA conversion - a key driver given high EV/EBITDA.
- Macro and sector multiples - re-rating risk if sector comparables compress.
- Balance sheet and capital structure impacts on enterprise value.
Wangsu Science & Technology Co.,Ltd. (300017.SZ) - Risk Factors
Wangsu Science & Technology Co.,Ltd. operates primarily in content delivery network (CDN) services, internet data center (IDC) services, cloud acceleration and related Internet infrastructure. Investors should weigh a set of company‑specific and industry risks that can materially affect cash flow, margins and valuation.- Competitive pressures: major cloud and CDN competitors (Alibaba Cloud, Tencent Cloud, BaishanCloud, ChinaNetCenter, others) compete on price, coverage and integrated solutions; aggressive capacity expansion could compress Wangsu's gross margins and ARPU (average revenue per user).
- Regulatory change: telecom, data localization, cross‑border data transfer rules, or new cybersecurity and content rules in China can increase compliance costs, restrict services, or force investment in local infrastructure.
- Foreign exchange volatility: a portion of revenue and costs tied to USD, HKD or other currencies exposes reported RMB revenue and profit to FX swings; a strengthening RMB reduces RMB-equivalent foreign revenue.
- Cybersecurity and operational risk: outages, DDoS attacks, or data breaches can cause service credits, customer churn and reputational damage-particularly important for large enterprise and media customers.
- Macroeconomic weakness: an economic downturn can reduce online advertising, streaming and e‑commerce traffic growth, lowering demand for CDN/acceleration and IDC capacity expansion.
- Technological disruption: rivals' innovation in edge computing, private CDN solutions, or proprietary protocols may erode Wangsu's market share or require elevated R&D/CAPEX to remain competitive.
| Metric / Exposure | Value (Estimated / 2023) | Implication for Risk |
|---|---|---|
| Annual Revenue | ≈ CNY 1.8-2.2 billion | Core scale-small shifts in market share produce noticeable revenue swings |
| Net Profit Margin | ≈ 5-8% | Thin margins amplify impact of price competition and cost inflation |
| R&D & CAPEX | R&D ~6-8% of revenue; CAPEX cyclical depending on network expansion | Higher required spend to defend technology can pressure free cash flow |
| Debt & Leases (total liabilities) | Estimated interest‑bearing debt ≈ CNY 0.6-1.0 billion | Leverage increases sensitivity to interest rates and operating cash flow declines |
| International / FX Exposure | ~10-15% of revenue linked to non‑RMB currencies | FX moves can swing reported revenue/profits; hedging may be partial |
| Customer concentration | Top 10 customers may represent ~30-40% of revenues | Loss of a handful of large accounts could materially reduce topline |
- How these risks translate to investor outcomes:
- Revenue risk: a 5-10% market share loss or demand slowdown could cut revenue by CNY 100-250 million annually (based on estimated revenue band).
- Margin sensitivity: a 200-400 bps margin compression could reduce net profit by CNY 40-80 million on current estimates.
- Capital intensity: accelerated network buildouts to match competitors could increase CAPEX by several hundred million CNY over a 1-3 year period, pressuring free cash flow and possibly requiring financing.
- Cyber incident costs: severe outages or breaches historically can lead to remediation, fines and customer churn totaling tens of millions CNY depending on scope.
Wangsu Science & Technology Co.,Ltd. (300017.SZ) - Growth Opportunities
Wangsu Science & Technology Co.,Ltd. (300017.SZ) stands at an inflection point where its legacy content delivery network (CDN) capabilities can be scaled into higher-value cloud, data, and security services. Key drivers and tactical initiatives that could materially affect future revenue and margins include product expansion, strategic alliances, market share capture from foreign exits, R&D acceleration, geographic footprint growth, and industry diversification.- Cloud computing & edge services - leveraging existing edge nodes and transmission assets to offer IaaS/PaaS and edge computing for latency-sensitive apps.
- Big data & analytics - monetizing network telemetry and customer traffic data into analytics platforms and managed data services.
- Cybersecurity offerings - bundling DDoS protection, WAF, and managed security services with CDN and cloud solutions to increase ARPU.
- Strategic partnerships - deepening alliances (e.g., Tencent Cloud) to co-sell, integrate billing, and expand customer pipelines.
- Geographic expansion - entering underserved domestic and regional markets (Southeast Asia, Central China) to deploy low-cost PoPs and capture new customers.
- Diversification into adjacent industries - media streaming platforms, gaming, IoT connectivity, and SaaS enablement for recurring revenue.
| Metric / Item | Value (FY or Note) |
|---|---|
| Reported Revenue (approx.) | RMB 1.8-2.2 billion (FY2022-FY2023 range, company historical scale) |
| R&D Spend | ~6-10% of revenue (target range to support cloud, data, security roadmap) |
| CDN Market Opportunity from Akamai Exit | Akamai ceasing China CDN ops by June 2026 - potential incremental market share: 5-12% of China CDN demand in target verticals |
| Strategic Partner | Tencent Cloud - channel and technical collaboration (co-selling and integration potential) |
| Typical Gross Margin Expansion Path | From CDN baseline (~30-40%) toward blended cloud/security margins (~40-55%) as higher-value services scale |
| Target ARPU Uplift | Potential +10-30% ARPU per customer by bundling cloud, data, and security services |
- Market timing: Akamai's announced withdrawal (complete by June 2026) opens procurement cycles now - aggressive capture plans in 2024-2026 can win enterprise contracts migrating from foreign CDN providers.
- Partnership leverage: Formalized integrations with Tencent Cloud can shorten sales cycles for cloud-adjacent products and provide pipeline access to Tencent's large SaaS and gaming clients.
- R&D prioritization: Allocating ~8-10% of revenue toward product engineering (edge computing, AI-driven caching, security automation) can accelerate product-market fit and create licensing or managed-service revenue.
- Geographic & vertical focus: Prioritize regions and sectors with high latency/survivability demands (gaming, live streaming, e-commerce peak events) and underserved second-tier cities for new PoP rollouts.
- Diversification execution: Launch pilot offerings for managed security and data analytics with existing top-100 customers to prove cross-sell economics before broad roll-out.
Wangsu Science & Technology Co.,Ltd. (300017.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.